Scarica l'app Stockscreener
20.95
5.46%
-1.21
Dopo l'orario di chiusura:
21.10
0.15
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$22.16
Aprire:
$22.021
Volume 24 ore:
2.88M
Relative Volume:
1.38
Capitalizzazione di mercato:
$2.11B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-11.57
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+2.44%
1M Prestazione:
+22.16%
6M Prestazione:
-19.36%
1 anno Prestazione:
-29.72%
Intervallo 1D:
$20.83
$22.35
Intervallo di 1 settimana:
$20.41
$22.80
Portata 52W:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
20.95 | 2.23B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Can Beam Therapeutics Inc. stock recover from recent declineSky-high return potential - jammulinksnews.com
What institutions are buying Beam Therapeutics Inc. stock nowOutperformance with explosive growth - jammulinksnews.com
Beam Therapeutics Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com
What analysts say about Beam Therapeutics Inc. stockFree High-Return Strategy Alerts - jammulinksnews.com
Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN
Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com
Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com
Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener
3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail
BEAM-101 shows sustained benefits as treatment for sickle cell - Sickle Cell Disease News
Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? - Yahoo Finance
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo Finance
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com
Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):